The list below displays information about clinical trials sponsored by Ipsen.
Only interventional studies that have started within the last 20 years and completed within the 2 last years will be displayed.
The study results will be available on ClinicalTrials.gov from 12 months after the end of the study.
Last Data Refreshed @ 21-Jan-2025 15:02:35 UTC
Filters
Condition
Status
Phase
Country
Showing : 1 – 5 of 13 clinical trials
Precocious Puberty
Decapeptyl
France
Completed
Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty
The purpose of the study is to assess the efficacy of triptorelin 11.25 mg pamoate in the delay of premature onset of puberty in girls less than 9 years and boys less than 10 years. This is measured by assessing the proportion of children who have a suppressed Luteinizing Hormone (LH) response to Gonadotropin Releasing Hormone (GnRH) test performed 3 months after injection with triptorelin 11.25 mg.
Precocious Puberty
Decapeptyl
France
Completed
Effects of Triptorelin Pamoate in Children With Precocious Puberty – Follow up Study
The purpose of the protocol is to assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or stabilisation of sexual maturity until the end of the study.
Endocrine Tumors
Somatuline
United States of America (the)
United Kingdom of Great Britain and Northern Ireland (the)
Spain
Slovakia
Sweden
Poland
Belgium
Austria
Italy
Germany
India
France
Czechia
Denmark
Completed
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
Acromegaly
Somatuline
Denmark
Czechia
France
Greece
Germany
Italy
Netherlands (Kingdom of the)
Sweden
Spain
United Kingdom of Great Britain and Northern Ireland (the)
Completed
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
The main aim of this study is to assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep sub-cutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via sub-cutaneous injection given once or twice a week) on IGF-1 levels over 28 weeks in acromegalic patients. The primary endpoint will be the percentage of acromegalic patients with normalised (age and sex adjusted) IGF-1 level at the end of the co-treatment period.
Non Functioning Entero-pancreatic Endocrine Tumour
Somatuline
United Kingdom of Great Britain and Northern Ireland (the)
United States of America (the)
Spain
Slovakia
Belgium
Poland
Italy
India
France
Czechia
Completed
Study of Lanreotide Autogel 120mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour
The purpose of this extension study is to assess the long term safety of patients with neuroendocrine tumour, who are treated with lanreotide Autogel and who participated in a previous study, 2-55-52030-726.